Join our daily newsletter At The Bell to receive exclusive market insights
- Recce Pharmaceuticals (RCE) has released positive safety data from its second cohort of subjects for its Phase I intravenous clinical trial of RECCE 327 (R327)
- R327 is designed to treat serious bacterial infections including sepsis.
- The second cohort demonstrated safety and tolerability among seven healthy male subjects who were intravenously dosed with 150mg of R327
- An independent safety committee has approved an increase in dosage to 500mg in the third cohort
- Shares were trading 2.69 per cent higher today at $1.34 at the end of the trading day
Recce Pharmaceuticals (RCE) has released positive safety data from its second cohort of subjects for its Phase I intravenous clinical trial of RECCE 327 (R327).
R327 is designed to treat serious bacterial infections including sepsis.
The second cohort demonstrated safety and tolerability among seven healthy male subjects who were intravenously dosed with 150mg of R327.
There were no clinically significant changes in vital signs, clinical, adverse events, or laboratory parameters.
Based upon the clinical data readouts, an independent safety committee has approved a tenfold increase from the initial dosing in cohort one (50mg) or a threefold increase from cohort two (150mg).
Cohort three will consist of seven to ten healthy subjects who will receive dosage of R327 at 500mg.
Subjects are expected to be recruited this week and dosed immediately at Adelaide’s CMAX clinical trial facility.
Chief Executive Officer James Graham said he is pleased with the results.
“We are pleased to see R327 (150mg) successfully tolerated as an intravenous infusion in Cohort Two subjects,” he said.
“Having successfully cleared two dosing levels (50mg and 150mg) we look forward to embarking upon this next significant milestone.”
The study is on track to have all Phase I dosing complete by the second quarter of this year.
Shares were trading 2.69 per cent higher today at $1.34 at the end of the trading day.
